Integrum

Integrum EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Integrum (INTEG B.ST) as of Nov 14, 2026 is -1,366.09 %. In the previous year, Year-over-Year EBITDA Growth was 111.83 % — a change of -1,321.53% (lower).

EBITDA Growth YoY

-1,366.09 %

YoY

-1,321.53%

Last updated:

Year-over-Year EBITDA Growth of Integrum is 2025 -1,366.09 % . Year-over-Year EBITDA Growth of Integrum was 2024 111.83 % . It decreases by -1,321.53% lower compared to the previous year.

The Integrum EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-213.01 SEK
Jan 1, 2019
-31.56 SEK
Jan 1, 2020
37.19 SEK
Jan 1, 2021
96.49 SEK
Jan 1, 2022
-2,453.22 SEK
Jan 1, 2023
-78.00 SEK
Jan 1, 2024
111.83 SEK
Jan 1, 2025
-1,366.09 SEK
The Integrum EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-1,366.09 %-1,321.53%
111.83 %-243.37%
-78.00 %-96.82%
-2,453.22 %-2,642.55%
96.49 %+159.43%
37.19 %-217.86%
-31.56 %-85.19%
-213.01 %-93.05%
-3,064.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integrum Stock analysis

What does Integrum do? Integrum AB generates revenue through the sale of medical devices, primarily the OPRA Implant System, which enables osseointegration for direct skeletal attachment of artificial limbs. The company also offers neural prosthetics technology, allowing bionic prostheses to connect directly to bone, nerves, and muscles, alongside a treatment method for phantom limb pain using machine learning, augmented reality, and virtual reality. Prosthetic components required to link the OPRA Implant System to external prostheses are sold as part of the product suite. Customers include individuals with amputations seeking advanced prosthetic solutions, with the company targeting medical professionals and healthcare providers who recommend and implement these systems. The OPRA Implant System, neural prosthetics, and phantom limb pain treatment are key revenue drivers, with the company focusing on high-end medical devices for specialized applications. Prosthetic components serve as complementary products, supporting the primary systems. The business model relies on direct sales to healthcare institutions and clinics specializing in prosthetics and rehabilitation, where the technology is integrated into patient care pathways. Integrum AB's product portfolio is centered around innovative medical solutions for amputees, with the OPRA Implant System as the flagship offering. The neural prosthetics and phantom limb pain treatment methods differentiate the company in the medical device market, addressing both functional and therapeutic needs. Sales of prosthetic components further enhance revenue streams by supporting the full integration of the implant system with external prosthetic devices. Integrum is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrum stock

Year-over-Year EBITDA Growth of Integrum is -1,366.09 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Integrum since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Integrum historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Integrum

All Key Metrics — Integrum